Montelukast
Singulair (montelukast) is a small molecule pharmaceutical. Montelukast was first approved as Singulair on 1998-02-20. It is used to treat allergic rhinitis perennial and asthma in the USA. The pharmaceutical is active against cysteinyl leukotriene receptor 1. In addition, it is known to target uracil nucleotide/cysteinyl leukotriene receptor and cytochrome P450 2C8.
Download report
Favorite
COVID-19
Top Prescription Drugs
Commercial
Trade Name
FDA
EMA
Singulair (generic drugs available since 2012-08-03)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
montelukast sodium | ANDA | 2023-06-07 |
singulair | New Drug Application | 2021-06-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
allergic rhinitis perennial | EFO_1001417 | D012221 | J30.89 |
asthma | EFO_0000270 | D001249 | J45 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
306 clinical trials
View more details

Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Asthma | D001249 | EFO_0000270 | J45 | 13 | 30 | 40 | 43 | 19 | 140 |
Healthy volunteers/patients | — | 15 | — | — | 1 | 2 | 18 | ||
Allergic rhinitis | D065631 | J30.9 | 3 | 2 | 2 | 9 | 1 | 17 | |
Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | — | 1 | 11 | 3 | 1 | 16 |
Exercise-induced asthma | D001250 | J45.990 | 1 | — | 4 | 2 | 1 | 8 | |
Allergic rhinitis perennial | D012221 | EFO_1001417 | J30.89 | — | — | 5 | 2 | — | 7 |
Bronchiolitis obliterans | D001989 | EFO_0007183 | — | 3 | — | 1 | — | 4 | |
Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | — | 2 | 2 | — | 4 |
Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | — | — | 3 | 1 | 4 |
Cough | D003371 | HP_0012735 | R05 | — | 1 | — | 2 | 1 | 4 |
Show 26 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Covid-19 | D000086382 | U07.1 | — | 1 | 3 | — | 2 | 6 | |
Bronchiolitis | D001988 | HP_0011950 | — | 2 | 1 | — | 3 | 6 | |
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 3 | 1 | 1 | — | — | 5 |
Status asthmaticus | D013224 | — | 2 | 2 | — | 1 | 3 | ||
Eosinophilic esophagitis | D057765 | EFO_0004232 | K20.0 | 1 | — | 1 | — | 1 | 3 |
Lung diseases | D008171 | EFO_0003818 | J98.4 | — | 1 | 1 | — | 1 | 2 |
Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | 2 | 1 | — | — | 2 |
Disease | D004194 | EFO_0000408 | R69 | — | — | 1 | — | — | 1 |
Dengue | D003715 | A90 | — | 1 | 1 | — | — | 1 | |
Severe dengue | D019595 | A91 | — | 1 | 1 | — | — | 1 |
Show 8 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple myeloma | D009101 | C90.0 | 1 | 1 | — | — | — | 2 | |
Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 2 | — | — | — | 2 |
Bronchopulmonary dysplasia | D001997 | P27.8 | 1 | 1 | — | — | — | 2 | |
Myeloid leukemia acute | D015470 | C92.0 | — | 1 | — | — | — | 1 | |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | — | 1 | — | — | — | 1 | |
Interstitial lung diseases | D017563 | EFO_0004244 | J84.89 | — | 1 | — | — | — | 1 |
Cryptogenic organizing pneumonia | D018549 | EFO_1001300 | J84.116 | — | 1 | — | — | — | 1 |
Food-drug interactions | D018565 | — | 1 | — | — | — | 1 | ||
Immune system diseases | D007154 | D89.9 | 1 | 1 | — | — | — | 1 | |
Sars-cov-2 | D000086402 | — | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | 1 | 2 |
Respiration disorders | D012120 | J00-J99 | 2 | — | — | — | — | 2 | |
Anterior cruciate ligament injuries | D000070598 | 1 | — | — | — | — | 1 | ||
Neonatal sepsis | D000071074 | HP_0040187 | 1 | — | — | — | — | 1 | |
Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | — | 1 |
Drug interactions | D004347 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Inflammation | D007249 | — | — | — | — | 2 | 2 | ||
Nephrotic syndrome | D009404 | EFO_0004255 | N04 | — | — | — | — | 1 | 1 |
Eosinophilia | D004802 | HP_0001880 | D72.1 | — | — | — | — | 1 | 1 |
Crest syndrome | D017675 | M34.1 | — | — | — | — | 1 | 1 | |
Depression | D003863 | F33.9 | — | — | — | — | 1 | 1 | |
Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | — | — | 1 | 1 |
Chronic renal insufficiency | D051436 | N18 | — | — | — | — | 1 | 1 | |
Conductive hearing loss | D006314 | HP_0000405 | H90.2 | — | — | — | — | 1 | 1 |
Erythema nodosum | D004893 | HP_0012219 | L52 | — | — | — | — | 1 | 1 |
Leprosy | D007918 | EFO_0001054 | A30 | — | — | — | — | 1 | 1 |
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | MONTELUKAST |
INN | montelukast |
Description | Montelukast is a member of quinolines, a monocarboxylic acid and an aliphatic sulfide. It has a role as a leukotriene antagonist, an anti-asthmatic drug and an anti-arrhythmia drug. It is a conjugate acid of a montelukast(1-). |
Classification | Small molecule |
Drug class | antiasthmatics/antiallergics (not acting primarily as antihistamines): leukotriene receptor antagonists |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1 |
Target
Agency Approved
CYSLTR1
CYSLTR1
Alternate
GPR17
GPR17
CYP2C8
CYP2C8
Organism
Homo sapiens
Gene name
GPR17
Gene synonyms
NCBI Gene ID
Protein name
uracil nucleotide/cysteinyl leukotriene receptor
Protein synonyms
G-protein coupled receptor 17, P2Y-like receptor, R12, UDP/CysLT receptor
Uniprot ID
Mouse ortholog
Gpr17 (574402)
uracil nucleotide/cysteinyl leukotriene receptor (Q80UD2)
Variants
Clinical Variant
No data
Financial
Singulair - Organon
$
€
£
₣

Mock data
Subscribe for the real data
Subscribe for the real data

Mock data
Subscribe for the real data
Subscribe for the real data
Singulair - Merck Sharp & Dohme
$
€
£
₣

Mock data
Subscribe for the real data
Subscribe for the real data

Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,567 documents
View more details
Safety
Black-box Warning
Black-box warning for: Montelukast sodium, Singulair
Adverse Events
Top Adverse Reactions

Mock data
Subscribe for the real data
Subscribe for the real data
809 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more